English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In every recent year, new cardiovascular outcome studies are published, illuminating our understanding regarding diabetes medications with cardiovascular protection, and we have discussed these in our previous editorials.1–6 In 2020 two new studies from the sodium glucose transporter 2 (SGLT2) inhibitor class and one from the glucagon-like peptide-1 receptor agonist (GLP-1RA) class of antidiabetic medications are worth highlighting. Each provided new information to help our understanding about the cardioprotective benefits of these classes so that we can further improve patient care. On 16 June 2020, during the 80th Scientific Sessions of the American Diabetes Association virtual meeting, the results of the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV) study were presented and have since been published in the New England Journal of Medicine.7,8 On 29 August 2020, during the European Society of Cardiology – The Digital Experience Congress 2020, the results of the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction (EMPEROR-Reduced) were presented and published simultaneously in the New England Journal of Medicine.9,10 The study was then presented in detail on 24 September 2020 during the European Association for the Study of Diabetes Virtual Congress (EASD) 2020.11 With regard to the GLP-1RA class, some further cardiovascular outcome data were presented at the EASD 2020 in the form of a post hoc analysis of pooled data from the LEADER, SUSTAIN 6 and PIONEER 6 cardiovascular outcome studies.12

the british journal of diabetes

Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020